Compound News and Research

RSS

Aeolus completes $1.0M financing to initiate human clinical studies of AEOL 10150 for cancer

Aeolus Pharmaceuticals, Inc. announced today that it has completed a $1.0 million financing with two existing institutional shareholders, both of which are affiliates of Xmark Opportunity Partners, LLC.

13 Aug 2010

Akela reports $0.1M net income for second-quarter 2010 vs. $1.1M net loss for same period in 2009

Akela Pharma, Inc., a leader in the development of therapeutics for the treatment of pain, and the company's wholly owned subsidiary, PharmaForm, today announced its financial results for the three and six months ended June 30, 2010.

13 Aug 2010

Cancer Research Technology grants Valirx global rights to develop VAL 201 for cancer treatment

Cancer Research Technology has signed a deal to provide biotech company ValiRx plc with the global rights to develop a promising compound to treat hormone-resistant prostate cancer.The compound, now called VAL 201, has been shown in pre-clinical tests in mice to stop growth of tumours which have been unresponsive to hormone treatments. VAL 201 blocks genes which can cause prostate cancer to develop. The compound has been shown to be effective in treating mice with breast and prostate cancer and is now rapidly progressing towards the first clinical trials in patients.

13 Aug 2010

Astex and MMRC commence Phase II clinical trial of AT7519 CDK inhibitor in multiple myeloma

Astex Therapeutics, the UK-based biotechnology company developing targeted therapies for oncology and virology, and the Multiple Myeloma Research Consortium announced today the initiation of a Phase II clinical trial of the cyclin-dependent kinase inhibitor, AT7519, to treat patients with relapsed or refractory multiple myeloma, an incurable blood cancer. The trial is designed to investigate both single agent and combination activity of AT7519 with bortezomib (Velcade®).

13 Aug 2010

Aeterna Zentaris second-quarter revenues decrease to $5.6 million

Aeterna Zentaris Inc., a late-stage drug development company specialized in oncology and endocrinology, today reported financial and operating results for the second quarter ended June 30, 2010.

12 Aug 2010

Amorfix first-quarter fiscal 2011 net loss from operations increases to $1,724,745

Amorfix Life Sciences, a product development company focused on misfolded protein diseases, today announced its operational and financial results for the three months ended June 30, 2010.

12 Aug 2010

ALLOZYNE signs worldwide, co-exclusive licensing agreement with Sigma-Aldrich

ALLOZYNE Inc. announced today the signing of a worldwide, co-exclusive licensing agreement with Sigma-Aldrich giving ALLOZYNE a license for the use of cycloaddition chemistry in the development of therapeutics and diagnostics. Sigma-Aldrich currently holds broad, worldwide intellectual property for the use of cycloaddition chemistry to conjugate biomolecules.

12 Aug 2010

Evotec revenues for first-half of 2010 increase 33% to € 25.0 m

Evotec AG today reported financial results and corporate updates for the first half of 2010.

12 Aug 2010

Pathway's drug development milestone triggers $4.5M tranche of Series A private equity placement

Pathway Therapeutics, a drug discovery and development company founded in New Zealand, announced that it has met an important drug development milestone triggering a US$4.5 million fourth tranche of its Series A private equity placement. The financing was led by GBS Venture Partners, Australia and CM Capital Investments, Australia with co-investors the Breast Cancer Research Trust, the Trans-Tasman Commercialisation Fund, and the New Zealand Venture Investment Firm.

12 Aug 2010

K-State researcher receives grant from NIH to continue cancer research

Understanding how cancer cells communicate with each other and how to enhance their receptiveness to drug treatments is the focus of promising work by a Kansas State University researcher.Annelise Nguyen, assistant professor of toxicology in the department of diagnostic medicine and pathobiology at K-State's College of Veterinary Medicine, recently received a $370,000 grant from the National Institutes of Health to continue her cancer research.

12 Aug 2010

Ohio State University procures IonFlux 16 high throughput automated patch clamp instrument

Fluxion Biosciences, Inc. announced today that the Ohio State University Department of Pharmacology has purchased the IonFlux 16, the first high throughput automated patch clamp instrument of its kind geared towards the academic researcher. The IonFlux instrument will enable large scale pharmacology experiments on this group's nAChR targets, which previously were not feasible using a manual patch clamp rig.

From Fluxion Biosciences 11 Aug 2010

PolyMedix's PMX-60056 Phase 1B/2 dose-ranging clinical study for heparin reversal meets study endpoints

PolyMedix, Inc., an emerging biotechnology company focused on developing new therapeutic drugs to treat acute cardiovascular disorders and infectious diseases, has successfully completed a Phase 1B/2 dose-ranging clinical study with PMX-60056, a synthetic small-molecule designed to reverse heparin and low molecular weight heparin anticoagulants.

11 Aug 2010

PregLem announces exclusive in licensing agreement with Merck Serono for Bentamapimod

PregLem, the Swiss specialty biopharmaceutical company focused on women's reproductive medicine, announces a world-wide, exclusive in licensing agreement for Bentamapimod, a novel, orally active, Jun Kinase Inhibitor from Merck Serono for an undisclosed amount. PregLem will develop the compound for the prevention of post-surgical abdominal adhesions and endometriosis in patients with tubal ligation or comparable effective contraception.

11 Aug 2010

Tamir Biotechnology's three compounds effective show potential for yellow fever

Tamir Biotechnology, Inc.(formerly Alfacell Corporation) announced today that scientists supported by the National Institute of Allergy and Infectious Diseases (NIAID) confirmed that testing of three of our company's compounds showed in vitro results rarely seen before by the U.S. government for yellow fever.

11 Aug 2010

Entelos receives patent for PhysioLab virtual patient technology

Entelos, Inc. today announced that the United States Patent and Trademark Office has issued U.S. Patent No. 7,774,182, entitled "Apparatus and Method for Validating a Computer Model." This patent was issued to Entelos for its invention of an innovative computer-implemented method for validating multiple virtual patients within a computer model. The PhysioLab virtual patient technology allows Entelos life scientists and engineers to more rapidly evaluate the safety and efficacy of new therapeutics in a diverse population of patients. This predictive power is integrated into our PhysioLab platforms, which have been used by our pharmaceutical and consumer product customers for over a decade to dramatically reduce the risk, time, and cost of product development.

11 Aug 2010

Dr. Hastings receives grant for Spinal Muscular Atrophy research

Michelle Hastings, PhD, Assistant Professor in the Department of Cell Biology and Anatomy, in the Chicago Medical School of Rosalind Franklin University of Medicine and Science, has been awarded a five-year $1.68 million grant from the National Institutes of Health to support her research aimed at investigating treatments for the fatal children's disease, Spinal Muscular Atrophy (SMA).

11 Aug 2010

Sinobiopharma inks agreement with Lianhuan to co-develop, manufacture and commercialize Eplerenone

Sinobiopharma, Inc., an innovative biopharmaceutical products company with primary operations in China, today announced that the Company, through its wholly-owned subsidiary Dong Ying Pharmaceutical Co., Ltd., has signed an agreement with Jiangsu Lianhuan Pharmaceuticals Co., Ltd. to co-develop, manufacture and commercialize Eplerenone, a therapeutic agent formulated to treat high blood pressure and vascular diseases.

11 Aug 2010

ACT signs agreement to select novel clinical candidates for two cancer metabolic programs

Advanced Cancer Therapeutics (ACT), a privately held company dedicated to bringing new anti-cancer therapies to market, today announced that it has signed an exclusive agreement to leverage the translational research expertise of Dr. Jason Chesney, Associate Professor, Department of Medicine at the University of Louisville's James Graham Brown Cancer Center (Brown Cancer Center), to identify new clinical candidates for the prevention and treatment of cancers against two key cancer metabolic targets.

11 Aug 2010

Analysis finds no evidence that inclusion of retinyl palmitate in sunscreens can cause cancer

Despite previous concerns about the cancer-causing potential of sunscreens containing retinyl palmitate (vitamin A), an independent analysis published online in the Journal of the American Academy of Dermatology determined that there is no evidence that the inclusion of retinyl palmitate in sunscreens can cause cancer in humans.

10 Aug 2010

FDA grants Orphan Drug Designation to YM BioSciences' JAK1/2 inhibitor

YM BioSciences Inc., announced that the Office of Orphan Products Development of the U.S. Food and Drug Administration has granted Orphan Drug Designation to the Company's highly-selective JAK1/2 inhibitor, CYT387, for the treatment of myelofibrosis, a chronic debilitating unmet medical need, in which a patient's bone marrow is replaced by scar tissue, and for which treatment options are limited or unsatisfactory.

10 Aug 2010

Compound News and Research

Aeolus completes $1.0M financing to initiate human clinical studies of AEOL 10150 for cancer

Akela reports $0.1M net income for second-quarter 2010 vs. $1.1M net loss for same period in 2009

Cancer Research Technology grants Valirx global rights to develop VAL 201 for cancer treatment

Astex and MMRC commence Phase II clinical trial of AT7519 CDK inhibitor in multiple myeloma

Aeterna Zentaris second-quarter revenues decrease to $5.6 million

Amorfix first-quarter fiscal 2011 net loss from operations increases to $1,724,745

ALLOZYNE signs worldwide, co-exclusive licensing agreement with Sigma-Aldrich

Evotec revenues for first-half of 2010 increase 33% to € 25.0 m

Pathway's drug development milestone triggers $4.5M tranche of Series A private equity placement

K-State researcher receives grant from NIH to continue cancer research

Ohio State University procures IonFlux 16 high throughput automated patch clamp instrument

PolyMedix's PMX-60056 Phase 1B/2 dose-ranging clinical study for heparin reversal meets study endpoints

PregLem announces exclusive in licensing agreement with Merck Serono for Bentamapimod

Tamir Biotechnology's three compounds effective show potential for yellow fever

Entelos receives patent for PhysioLab virtual patient technology

Dr. Hastings receives grant for Spinal Muscular Atrophy research

Sinobiopharma inks agreement with Lianhuan to co-develop, manufacture and commercialize Eplerenone

ACT signs agreement to select novel clinical candidates for two cancer metabolic programs

Analysis finds no evidence that inclusion of retinyl palmitate in sunscreens can cause cancer

FDA grants Orphan Drug Designation to YM BioSciences' JAK1/2 inhibitor

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News